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Bacterial infections arefrequently thedirect orprincipal underlying causeofhuman
neonatal deaths. The group B streptococci (GBS)' compose the predominant group
of gram-positive bacteria responsible for severe or life-threatening infections. In-
fants born prematurely, and infants born more than 18 h after the amniotic mem-
brane has ruptured, are at a higher risk for early-onset infection. Late-onset GBS
infections occur in infected healthy newborns up to 2-3 mo of age. Regardless of
the timeofonset, a significant percentage ofthese infections result in death, or per-
manent disability (1).
GBS are distinguished from other streptococci by their conserved group-specific
polysaccharide, and are furtherphenotyped based on the reactivity oftheir capsule
polysaccharide with type-specific antisera (2). In humans, although any capsuletype
(Ia, Ib, II, and III) may cause early onset sepsis, type III GBS are associated with
the majority ofearlyonset meningitis, andlateonset sepsis and meningitis (3). GBS
capsule expression directly correlates with GBS virulence (4).
It isgenerallyagreed that type-specific capsule, butnot group polysaccharide-specific
antibodies, provideGBS immunity (2, 5-8). Among healthyand infectednewborns,
the lowest infection rate correlates with elevated maternal anti-type-specific capsule
titers (5, 9). Moreover, human maternal sera with the highest anticapsule activity
passively protect GBS-infected rodents (9, 10). These data corroborate the protec-
tive activity ofheterologous capsule antisera and murine anticapsule mAbs (2, 6,
9). Heterologous antisera and mouse mAbs reacting with the group B polysaccha-
ride have consistently failed in animal protection studies (8, 10).
Human mAbs against specific pathogens may provide an effective and safe alter-
native, or adjunct treatment for neontal infections. Experiments using a protective
human mAb against another common neonatal pathogen, Escherichia toll Kl (11),
suggestedmAbs against otherprevalent bacteria might contribute towards reducing
the mortality from neonatal infections. This report describes the development of
human mAbs specific for the group B polysaccharide on GBS. The mAbs reacted
with all GBSserotypes and provided therapeuticprotection in neonatal rats infected
with either type III or type la GBS clinical isolates.
I Abbreviations used in this paper: GBS, group B streptococci; XIEP crossed immunoelectrophoresis.
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Materials and Methods
BacterialStrains, Antigens, andAntisera.
￿
The GBS reference strains and clinical isolates were
obtained as follows: type la: SS-615, SS-800, SS-881; type Ib: SS-618; type Ic : SS-700; type
II: SS-619; type III: SS-620 from Dr. R. Facklam (Centers for Disease Control (CDC), At-
lanta, GA); 090R from American Type Culture Collection (ATCC, No. 12386, Rockville,
MD) . A type III GBS clinical isolate, COH 31r/s (rifampin and streptomycin resistant) and
its isogenic, capsule-negative mutant COH 31-15 (3) used in crossed immunoelectrophoresis
(XIEP) were provided by Dr. C. Rubens, Childrens Orthopedic Hospital, Seattle, WA. This
insertion mutant was obtained using Tn916 transposon mutagenesis ofthe COH 31r/s parent.
The mutant was found to express the group B polysaccharide, but did not possess detectable
capsule. The additional 132 isolates were obtained from Seattle area hospitals (Childrens Or-
thopedic Hospital, Harborview Medical Center, Group Health Hospital, and Veterans Ad-
ministration Hospital), and from Dr. Joan FungTomc (Bristol-Myers Company, Microbi-
ology Culture Collection, Wallingford, CT). 29 ofthe clinical strains were isolated from blood
or cerebrospinal fluid, primarily in neonates. All isolates were confirmed as GBS using a
latex agglutination test kit (Streptex; Wellcome Diagnostics, Darford, England) and com-
mercial (anti-group B; Difco Laboratories, Inc., Detroit, MI) or CDC reference antisera (gener-
ously supplied by Dr. R. Facklam, CDC).
Non-GBS reference strains were obtained from: Pseudomonas aeruginosa F2 (ATCC No. 27313);
streptococcus group A (two isolates from Harboview Medical Center); streptococcus group
C (vaccine strain SS-188 [CDC]); streptococcus group D (vaccine strain SS-499 [CDC] and
a clinical isolate [Harboview Medical Center]); streptococcus group G (clinical isolate from
Dr. F. Tenover [Veterans Administration Hospital]); streptococcus group G (vaccine strain
SS-13 [CDC], ATCC No. 12394, six clinical isolates from Harborview Medical Center and
five from Group Health Hospital); Streptococcus mutans (ATCC No. 27607); Streptococcus sanguis
(ATCC No. 10557).
Serotype-specific antisera used in XIEP were raised in New Zealand white rabbits by
Lancefield's procedure (6). Group-specific polysaccharide antigen was purchased (Difco
Laboratories, Inc.). Bacteria were grown in Todd-Hewitt Broth modified for extra buffering
capacity by increasing the disodium phosphate eightfold (12). Cell wall digests of logarithmic
and stationary phase cultures were prepared by mutanolysin treatment (13).
ChemicalReagents.
￿
Unless otherwise noted, all chemical reagents were purchased from Sigma
Chemical Co., St. Louis, MO.
Lymphocyte Sources for Transformation.
￿
B lymphocytes were obtained from the peripheral
blood of normal humans, or cystic fibrosis patients hospitalized at Childrens Orthopedic Hos-
pital, and from tonsil fragments obtained from routine tonsillectomies performed on other-
wise normal patients at University Hospital, University of Washington, Seattle, WA.
Viral Transformationfor the Production ofHuman mAb.
￿
Human mononuclear cells were sepa-
rated from heparinized whole blood or tonsil cell suspensions by density gradient centrifuga-
tion through Lymphocyte Separation Media (Litton Bionetics, Charleston, SC) (14). The
mononuclear cells were depleted of T lymphocytes using a modified E-rosetting technique
(15). The E rosette-negative cells were washed once in Iscove's medium (Gibco Laboratories,
Grand Island, NY) containing 15 0 /'o (vol/vol) FCS, 2 MM L-glutamine, penicillin (100 U/ml),
streptomycin (100 Rg/ml) and resuspended in Iscove's-HAT (hypoxanthine [10-4 M),
aminopterin [4 x 10' M), and thymidine [1 .6 x 10-1 M]).
The HATsensitive EBVproducing cell line, 1A2, was used for the transformations (16).
IA2 cells in logarithmic growth phase were combined with E rosette-negative mononuclear
cells (30 :1) in Iscove's-HAT medium. 200 41 of the cell mixture containing 1,000-2,000 E
rosette-negative cells and 30,000-60,000 1A2 cells, were dispensed into each well of several
96-well round-bottomed microtiter plates. The cultures were incubated at 37'C in a humidified
chamber containing 6% C02, and were fed every 3-4 d by replacing one-half the culture
supernatant with fresh HAT medium. After 12-14 d, vigorous growth was generally apparent
in 100% of the wells. After the culture supernatants were collected for assaying antibody
activity, the cultures were fed with Iscove's medium without HAT.
Antibody ScreeningAssay.
￿
A standard ELISA protocol was used to screen culture superna-
tants for anti-GBS binding activity. This protocol has been previously described (11).RAFF ET AL.
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Lymphoblastoid Cell Cloning!
￿
Lymphoblastoid cells producing GBS antibodies were cloned
by sequential limiting dilution platings. Cells, diluted in Iscove's medium containing 15%
FCS, were seeded at densities between 20 and 2 cells/microtiter well in the absence of feeder
cells. After one to two rounds of plating at gradually reduced cell input, cells showing good
growth and antibody productionwere cloned by plating in 72-well Terasaki plates and visually
identifying wells containing single cells (17).
mAb Reactivity with ClinicalIsolates.
￿
The humanGBS mAbs were assayed by "dot blot"analysis
for reactivity with clinical isolates (11). A total of 132 GBS clinical isolates and five Lancefield
reference strains were tested in this manner.
Antibody Purification.
￿
High cell density (5 x 105 to 1 x 106 cells/ml), nutrient-exhausted
culture supernatant was concentrated by Minitan tangential flow ultrafiltration (Millipore
Corp., Bedford, MA) using PTHK 100,000 nominal molecular weight limitmembranes. The
mAbs were purified from concentrates by affinity chromatography on a murine anti-human
IgM mAb column (11). Purity was examined by SDS-PAGE followed by silver nitrate staining
(18), and antibody activity was assessed by ELISA as described above. Purified antibody prepa-
rations were assayed for pyrogen using the Limulus Amebocyte assay QCL-100 (M. A. Bi-
oproducts, Walkersville, MD).
Crossed Immunoelectmphoresis andImmunoblotting
￿
12 ml of l % agarose (SeaKem HGT; GMC
Corp., Rockland, ME) in Monthony buffer (19) was poured onto an 84 x 94 mm glass plate.
Wells punched in the solidified gel were filled flush with soluble antigen, and the first XIEP
dimension was run on a Multiphore electrophoresis unit (LKB Instruments, Inc., Gaithers-
burg, MD) at 200 V, 10°C, for 1.5-2 h. The electrophoretically separated antigens were precipi-
tated during electrophoresis into the second dimension antibody containing resolving gel
(10-15 wl antiserum/cm2) at 10°C, 2 V/cm for 18 h. After repeated washing in saline and
press/blotting, gels were either dried onto Gelbond (GMC Corp.) and stained with Crowle's
Double Stain (20) or used to prepare blots. XIEP gel protein precipitates were passively trans-
ferred to nitrocellulose. The pressed gels were reswelled in 0.1 M glycine-HCI, pH 2.5, for
15 min, removed from the glassplates, and sandwiched between nitrocellulose and blot paper.
Sandwiches were prepared as follows: two sheets of Whatman 3MM blotting paper soaked
in glycine-HCI were layered onto a glass plate, the reswollen XIEP gel was laid on top and
was carefully overlaid with nitrocellulose sheets soaked in electrophoresic transfer buffer (25
mM Tris, 192 mM glycine, pH 8.3, with 20% methanol), and the nitrocellulose sheets were
covered with four sheets ofdry blotting paper and a glass plate. After 15 min, the nitrocellu-
lose was blocked with PBS with Tween 20 (PBST) for at least1 h. Gels blotted onto nitrocellu-
lose paper were immersed in antibody containing culture supernatants for 1 h at room tem-
perature. After washing, antibody binding was detected using the substrate system described
for the dot blot analyses.
Blocking Experiments with Monosaccharides.
￿
Purified mAbs were mixed with individual
monosaccharides (a-L-rhamose, n-glucitol, n-galactose, N-acetylglucosamine, or methyl-a-
D-mannopyranoside at final concentrations of 0.1 kg/ml mAb and 20 mg/ml monosaccha-
ride. Antibody and monosaccharide mixtures were incubated for 45 min at room tempera-
ture, and assayed in the standard ELISA (described above).
Opsonophagocytic Studies.
￿
The opsonic assays were performed essentially as described pre-
viously (I1). Normal human serum adsorbed with GBS served as the complement source,
and freshly isolated human neutrophils were used as the phagocytic cell source (21). To deter-
mine the percentage of bacterial survival, colony forming units (CFU) from experimental
mixtures ofbacteria, mAb-containing culture supernatant, complement, and neutrophils were
compared with CFU from control mixtures lacking one or more of the components. For the
control mixtures, a non-GBS-reactive mAb was used in place of the GBS mAb, heat-inactivated
complementwas used in place ofactive complement, and buffer was used in place ofneutro-
phils. The data are reported as follows: 100 x 1- f(cfu remaining afterincubation with PMN,
complement, and test mAb)/(CFU remaining after incubation with PMN, complement, and
negative mAb)].
Protection Tests. For all experiments, initial broth culture tubes were inoculated using over-
night stationary phase cultures started from frozen maintained stock cultures. At logarithmic
growth phase, the tubes were centrifuged at 22°C, 4,550 g, for 10 min, washed once with908
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25 ml broth, and resuspended in same to the appropriate bacterial density. For each experi-
ment, dilutions of the bacterial source were plated on trypticase soy agar plates to quantitate
the challenge dose, and on blood agar plates to confirm culture purity.
2-3-d-old outbred Sprague-Dawley (BK:SD) rat pups and their dams were purchased from
Bantin and Kingman (Fremont, CA). Individual dams and their pups were housed in poly-
carbonate microisolator rat cages (Lab Products, Inc., Maywood, NJ), were given food and
water ad libitum, and were exposed to a 12-h light/dark photoperiod.
For injections, a repeating Hamilton dispenser (10 ul/button depressor, ASP S9630-1) was
loaded with a 0.5 ml Hamilton syringe fitted with a Leur tip (ASP 59660-55) attached to
a Butterfly" pediatric infusion set (25 x 3/4-inch needle with 12-inch tubing, No. 4506; Ped-
line Surgicals, Seattle, WA). To visualize movement of the colorless reagent solutions in the
tubing, an air gap followed by trypan blue dye progressed behind the bacteria or mAb.
A neonatal rat infection model was performed in the following ways: (a) To determine whether
the mAbs were protective if administered before infection (prophylactic), neonatal rats re-
ceived antibody 24 or 4 h before bacteria challenge. To avoid indirect mixing of antibody
and bacteria, mAb was administered to one dorsal thigh (40 41 at 1 mg/ml), followed by in-
traperitoneal infection with 5 LD5o (100-4,000 CFU) of bacteria (40 41).
(b) The prophylactic efficacy of the mAbs was also tested against infections caused by in
vivo passaged GBS. 18 h after intraperitoneal infection with GBS (1 LD5o), bacteria (pas-
saged) were recovered from the cardiac blood of rat pups exhibiting lethargy and pallor. An
aliquot of blood was mixed with an equal volume of 0 .8% trypan blue, and the CFU/ml of
blood were calculated after microscopic counting. The blood was diluted with Todd-Hewitt
Broth and 40 ul containing 5 LD5o (100-1,000 CFU) was injected intraperitoneally into pups
who 24 h previously had received prophylactic mAb (see above).
(c) The therapeutic activity was assessed in pups receiving mAbs after GBS challenge. An-
tibodies were administered intraperitoneally 4 h after challenge with 5 LD5o (80-500 CFU)
ofin vitro-grown GBS. At the time ofmAb injection, a sampling ofinfected pups were septic
(500-1,000 CFU/ml blood) with the infecting GBS strain.
In all experiments, the 40-wl dose of purified mAb contained less endotoxin (20 pg) than
the sensitivity limit of the colorimetric assay (see Materials and Methods above). Because
few negative mAb control rats survived, it is unlikely the observed protection was due to
nonspecific macrophage activation, or other endotoxin mediated effects. Negative control
mAbs were either Pseudomonas aeruginosa- (16) or E. coli Kl- (11) specific human mAbs. Treated
pups were examined twice daily for symptoms, and scored for survival.
Statistical Analysis.
￿
LD5o values were calculated by the method of Reed and Muench (22),
with 10 animals used for each bacterial concentration (data not shown). Significance of differ-
ences between mortality values in protection studies (n = 10-12) was determined by Fisher's
Exact Test of categorical data (23).
Results
Characterization of Group B Streptococcus Human mAbs.
￿
Master well supernatants from
18 human B cell EBV transformations were screened by ELISA on microtiter wells
coated with a pool of five GBS serotypes. Supernatants with binding activity were
subsequently assayed on individual GBS serotypes to separate serotype-specific from
cross-serotype reactions. From these transformations (>20,000 master wells), 104
master well supernatants reacted with all five GBS serotypes. In general, each super-
natant reacted comparably on all serotypes (Table 1).
mAb 4139 (IgM) was derived from the peripheral blood B cells of a donor with
cystic fibrosis, and antibody 3132 (IgM) from tonsillar B cells. Neither donor had
a known history of GBS infection. These mAbs were used in all experiments with
virtually identical results. However, in some cases, only data with the most frequently
used mAb are presented. The mAbs were further characterized by testing for cross-
reactivity against other streptococcal groups. Both mAbs reacted with typable andRAFF ET AL.
TABLE I
ELISA-based Crossreactivity of Group B Streptococcus Human mAb
` Anti-group B streptococcal human monoclonal antibody (IgM).
t Anti-P aeruginosa human monoclonal antibody (IgM).
§ ELISA value at OD49p.
nontypable GBS, and group G streptococci, but not otherstreptococcal groups. Cross-
reactivity between the group B and groupG streptococcal polysaccharides has been
reported (24) .
Clinical Isolate Reactivity.
￿
The potential forbindingto alarge number of clinical
isolates was investigated using a collection of GBS clinical isolates representing all
serotypes (Table II). The immunoblot nitrocellulose dot assay allowed the simul-
taneous testing of 132 clinical isolates using only 2 ml of mAb containing spent cul-
ture supernatant. 4B9 and 3D2 reacted with 132/132 of the clinical isolates. From
these data, it would appear the mAbs recognize a GBS epitope conserved among
clinical isolates obtained from different patient populations hospitalized in several
U. S. cities.
Biochemical Analysis UsingXIEPImmunoblotting
￿
XIEP is useful foridentifying in-
dividual interactions between heterogeneous crude antigen samples and polyvalent
antisera. Complex cell wall digests, or purified antigen preparations, are first sepa-
rated horizontally (first dimension), and then immunoprecipitated by the antisera
in the second, vertically run agarose slab (second dimension). AfterCrowle staining,
TABLE II
Group B Streptococcus Human mAb Reactivity with Human Clinical Isolates
` Isolates obtained from Seattle area hospitals.
t Isolates obtained from all other United States Hospitals .
S Value in parentheses are the percentage of isolates represented by each serotype.
II Nontypable for type-specific capsule.
Reactive with both type 11 and type III capsule typing reagents .
909
Serotype Total tested Seattle` Other U.S.1
la 0 (0)S 0 0
Ib 26 (20) 24 2
Ic 25 (19) 21 4
II 25 (19) 16 9
III 51 (39) 41 10
NTII 3 (2) 3 0
II/III, 2 (1.5) 1 1
Total 132 106 26
Strain Serotypes
ELISA
Positive`
reactivity
Negativel
SS-615 la/ - 2 .335 0.14
SS-618 Ib/c 2 .29 0.14
SS-700 Ia/c 33 .0 0.15
SS-619 II/ - 2 .01 0.13
SS-620 III/c 2.13 0.13
No bacteria 0.35 0.1291 0
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FIGURE 1 .
￿
XIEP gels and im-
munoblots. (A) Stained XIEP
gels ofcell wall digests . Antigens
run in the first dimension were
cell wall digest of the type III
clinical isolateCOH31r/s(pan-
els 1, 2, and 3) or the capsule-
deficient isogenic mutantCOH
31-15 (4 and 5), or purified
groupB antigen (6) .The second
dimension gels contained the
following antisera : anti-group
B polysaccharide and anti-type
specific (1 and 4), anti-group B
polysaccharide only (2, 5, 6), or
anti-type specific only (3) . (B)
Immunoblots of XIEP gels .
Panels 7, 8, and 9 contained
digests ofstrainCOH 31-15 and
both monospecific sera. (10, 11,
and 12) Purified group B anti-
gen and monospecific anti-
group B sera . Vertical panel
pairs (7 and 10, 8and 11) were
immunoblotted with the GBS
mAbs 4B9 or 3132, and (9 and
12) with negative control mAb
(6F11) .
the number andthe localization of precipitant arcs help characterize antibodies and
antigens . In addition, mAb-containing culture supernatants can be used to immu-
noblot antigens precipitated with antisera . Ifpurified antigens are available as stan-
dards, a combination ofmethods can, at least indirectly, identify the antigen recog-
nized by a mAb.
The relative locations of immunoprecipitated group B polysaccharide and type-
specific capsule were determined by staining gels containing monospecific antisera .
Purified group B polysaccharide, immunoprecipitated with monospecific group B
antisera, was identified as aslower migrating molecule (Fig. 1 A, panel 6) . The clin-
ical isolate COH 31r/s and its isogenic capsule-deficient mutant, COH 31-15 (3),
provided GBS antigen sources differingonly by their capsule expression . The purified
group B carbohydrate arc corresponded to the reaction occurring when capsule-
deficient COH 31-15 digests were precipitated in the same group B antisera (Fig .
1 A, panel 5) . Compared with the group B peak, a more anodal precipitate was ob-
servedbetween digests of the encapsulated COH 31r/s strain and monospecific typeS m
E
E .x
0
0
0
80
60
40
20
0
FIGURE 2.
￿
Monosaccharide competition assays
to determinethe ability ofdifferent monosaccha-
ridesto block GBS-mAb binding. For each bar,
thepercentage maximumbinding(ordinate) was
obtained usingtheformula: 100 x 1 - [(ELISA
value in absence of competing monosaccha-
ride)/(ELISA value in presence of test competing
monosaccharide)]. Type la (strain H227, hatched
bar) and type III (strain 1334, solid bar) clin-
ical isolates were used to assay binding activity
None
￿
Rhomnose
￿
Glucitol
￿
Goloctose
￿
NAG
￿
afterincubating the mAbwith thetest monosac-
Competing Sugar
￿
charides.
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III capsule antisera (Fig. 1 A, panel 3). Other reference mAband antigen combina-
tions ensured there was no interference when several reactions were possible (Fig.
1 A, panels 1 and2) . Therelative positions ofthe two principal GBS surfaceantigens
served as references for the identification of antigens reacting with immunoblotted
mAbs.
The 4B9 and3D2 mAbs were immunoblotted against precipitated immune com-
plexes passively transferred to nitrocellulose paper. Both mAbs reacted with an an-
tigen in a similar location as antigen detected by the group B polysaccharide
monospecific antisera and digests of strain COH 31-15 (compare Fig. 1 A, panel
5 with Fig. 1 B, panels 10 and 11), or purified group B polysaccharide (compare
Fig. 1 A, panel 6 with Fig. 1 B, panel 7 and 8). The negative control mAb, 6F11
(anti-P. aeruginosa), did not react with the purified antigen, but did display a slight
nonspecific reaction against the cell wall digest (Fig. 1 B, panels 9 and 12, respec-
tively). When blotted against cell wall digests from the other capsule serotypes (Ia,
Ib, and II), the mAbs identified a similarly migratingmolecule (not shown). These
observations provide strong, albeit indirect, evidence that theGBS mAbs react with
a highly conserved group B polysaccharide epitope.
Monosaccharide Competition of Group B Streptococcus mAbs.
￿
Monosaccharide compe-
tition assays with the mAbs further characterized their GBS target. On GBS, only
the group B polysaccharide possesses a-L-rhamnose as a major structural compo-
nent. Group B polysaccharide antisera, mixed with a-L-rhamnose, is effectively
blocked from binding to bacteria-associated antigen (7). Purified mAbs were used
at 0.1 ug/ml, an antibody concentration typically representing 50% saturation against
intact bacterialELISAs. After combiningwith 20 mg/mlofrhamnose, glucitol, galac-
tose, or N-acetylglucosamine, the mAb and monosaccharide mixtures were tested
by ELISA for reactivity against intact GBS bacteria (Fig. 2). Only rhamnose (95%
inhibition) significantly interfered with mAb reactivity against type Ia or type III
isolates. These data, and those obtained by XIEP, provide strong evidence that mAbs
4B9 and 3D2 recognize an epitope on the group B polysaccharide.
Opsonization by the Group B Streptococcus mAbs.
￿
The functional activity ofthe mAbs
was tested against viable GBS in an opsonophagocytic assay. Combinations of GBS
mAbs, ahuman serumcomplement source, andhuman neutrophils were used against
clinical isolates and typing strains representing the five GBS serotypes. Both mAbs
effectively (80-97% reduction in CFU) mediated the opsonization and destruction
of bacterial strains from each serotype (Fig. 3, data shown only for mAb 4119). In
otherexperiments using additional type la, Ib, and III strains (data not shown) the91 2
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Opsonophagocytosis assays using
the GBS mAbs and five GBS serotypes.
The strainsused had the followingdesig-
nations: la (H227),. Ib (SS-618), Ia/c
(1546), II (F180), and III(1334). Foreach
bar, thepercentage survival (ordinate) was
obtained usingtheformula: 100 x [(CFU
remaining after incubation with PMN,
complement, and test mAb)/(CFU re-
mainingafterincubation with PMN, com-
plement, and negative mAb)].
Three control conditions for serotype
Ia are represented by the hatched bars
Io
￿
Ib Io/c II
￿
III
￿
Io
￿
Io
￿
Io
￿
labeled la (-PMN's), Ia (-C), and la
Serotype
￿
(PM"51 c-c' (-mAb)
￿
(-mAb).
￿
These control mixtures each
lacked one active component: (-PMNs)
buffer replacing neutrophils;(-C) heat-in-
activated complement; and (-mAb) nega-
tive control human mAb replacing GBS
mAb.
mAb consistently enhanced opsonization (80-95 % reductionin CFU). In each con-
trol condition, a different active reagent was omitted. Substituting active compo-
nents with a negative control human mAb, heat-inactivated human complement,
or PBS for neutrophils, each resulted in complete removalofopsonic activity. There-
fore, effective opsonic activity required both a GBS mAb and active complement.
The IgM class mAbs were not anticipated to be opsonic alone. Further, mAbs and
complement without neutrophils were ineffective in mediating direct bacteriolysis.
These assays clearly show the group B polysaccharide mAbs facilitate complement-
dependent opsonization of strains representing each GBS serotype.
Neonatal Rat Protection Studies.
￿
The ability of the mAbs to protect if given before
(prophylactic) or after(therapeutic) infection was examined in a neonatal rat model.
Attempts to avoid potential artefacts (e.g., reducedcapsule production resulting from
in vitrogrowth)necessitated usingdifferent variations of a standard rat model. mAb
was administered either (a) before infection with in vitro grown bacteria, (b) before
infection with in vivo passaged bacteria, or (c) after infection with in vitro grown
bacteria. In these experiments, rat pups were infected intraperitoneally with 5 LD5o
of each GBS strain and received 40 leg of purified mAb, either subcutaneously or
intraperitoneally. Litter-to-litter variation was minimized by dividing pups from in-
dividual litters (four to six litters/experiment) so all treatment groups were repre-
sented. This protocol provided internally controlled litters and larger experimental
groups when the data from several litters were pooled. Each protection experiment
(Fig. 4) represents the percentage survival from four to six identically treatedlitters.
The prophylactic activity of the mAbs was tested in pups receiving mAbs 24 h
before infection with in vitro grown GBS. 40 ttl of GBS or negative control mAb
(see Materials and Methods) were injected subcutaneously 24 h before challenge
with either a type III (1,000 CFU) or a type Ia (500 CFU) clinical isolate (Fig. 4,
A and B). Against both isolates, only the GBS mAb protected 100% (p < 0.001) of
the type la, and 90% (p < 0.001) of the type III-infected pups. In similar experi-
ments using other type la and III clinical isolates, 90-100% protection was consis-
tently observed (not shown). These data suggest that the group B polysaccharide100
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0
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> 60
,'n 40
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0
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FIGURE 4.
￿
Neonatal rat protection trials using the GBS
mAbs againsttype la (strain H227)andtype III(strain 1334)
clinical isolates. The human mAbs 3132 (closed circle) and
6F11 (open circle) were used in three protection models in
which neonatal rats were infected with type Ia or type III
GBS bacteria. Results from thethree models are shownas
follows: prophylactic (A) type Ia and (B) type III; in
vivo-passed bacteria (C type la and(D)type III; andthey-
, apeutic (E) type la and (F) type III. Also shown in F is a
prophylactic experiment with mAb administered 4 h be-
fore infection, 3132 (closed square) and 6F11 (open square).
mAbs provide prophylactic protection against infections caused by several in vitro
grown GBS strains.
Because in vitro growth may affect their sensitivity to the GBS mAbs, the clinical
isolates used above were first passaged through neonatal rats, and without subse-
quent in vitro growth, were used to infect rats. This approach was also intended
to provide the opportunity for enhanced in vivo dependent capsule production that
might decrease the accessibility of the group B polysaccharide to antibody. There-
fore, to be protective, the GBS mAbs must opsonize bacteria demonstrating in vivo
virulence. In fact, the LD50 of in vivo-passaged bacteria were reduced by 50%, com-
pared with the same strains grown in vitro. Blood from rats exhibiting lethargy and
pallor 18 h after a 1 LD5o infection, was used to infect pups that had previously re-
ceived mAb (24 h before). After microscopically counting the GBS, blood samples
were diluted to the appropriate bacteria concentration (CFU) and without addi-
tional processing, injected into several litters of rats pups. Comparable to the results
using in vitro grown bacteria, the GBS mAbs (40 ug) were protective against infec-
tionscaused by in vivo passed
CBS
(Fig. 4, Cand D). Complete protection was ob-
served (p < 0.001) among rats that received the GBS mAbs, and were infected with
either a type la (500 CFU) or atype III (300 CFU) strain. These data demonstrate
that bacteria surviving short-term in vivo growth remain sensitiveto the GBS mAbs.
The most stringent challenge fora protective mAb is the ability to protect or cure
septic animals. In contrast to the prophylactic model, a therapeutic mAb should
aid in clearing bacteria that have most likely disseminated into several organs. To
test their therapeutic efficacy the mAbs were administered 4 h after infection with
100 or 200 CFU (5 LD50). Cardiac blood samples drawn at the time of mAb injec-
tion (900 CFU/ml of blood for the type Ia and type III strains) confirmed the rats
were bacteremic. In these experiments (Fig. 4, E and F), mAb administered 4 h
after infection protected 80% (p < 0.001) of the type Ia and 100% (p < 0.001) of91 4
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the type III-infected rats. Negative control mAb-treatedanimalswere not significantly
protected (10% and 20%, respectively). Although 40 ug of each mAb were used in
these experiments, mAb titration experiments usually showed 5 gg of mAb were
able to protect 80% ofthe infected pups (not shown). These protection experiments
provide convincing evidence that GBS anti-group B polysaccharide mAbs possess
therapeutic protective activity against twoGBScapsuletypes. In addition, these mAbs
have provided protection against other GBS strains (Dr. Harry Hill, personal com-
munication), strongly suggesting the mAbs have protective activity against a broad
distribution of clinical strains.
Discussion
This report describes the first example of a group B polysaccharide mAb protec-
tive against infections caused by multiple GBS serotypes. The antibody-producing
cell lines were developed by EBV transformation of human B cells obtained from
donors without histories of previous GBS infections. The mAbs recognized 132/132
ofthe clinical isolates screened, indicating the epitope is conserved on GBS infecting
different patient types hospitalized in several geographical regions.
The antigen recognized by the cross-protective mAbs was shown to be the group
B polysaccharide using XIEP with immunoblotting, andmonosaccharide competi-
tion binding assays. Encapsulated (COH 31r/s) and unencapsulated (COH 31-15)
isogenic GBS strains (3), and a purified group B polysaccharide preparation provided
reference standards helpful in localizing capsule and group B polysaccharide XIEP
patterns. Immunoblots against strain COH 31-15 cell wall digests revealed the GBS
mAbs bound to molecules migrating to the same region as the group B polysaccha-
ride. These immunoblot patterns also corresponded to patterns obtained usingpurified
group B polysaccharide. These data strongly suggest the GBS mAbs recognize a
conserved epitope on the group B polysaccharide, which appears to be expressed
independently of capsule production (strain COH 31-15).
Although there have been other attempts (6, 8), this is the first report showing
a GBS antibody is able to opsonize GBS strains with different capsule types. Using
human mAbs with human serum (complement) and neutrophils, the GBS mAbs
opsonized GBS strains representing the five serotypes. To mediate bacteriocidal or
opsonic activity, antibody must interact with antigen (group B polysaccharide) in
a fashion leadingto complement binding and activation. Even though the GBS mAbs
and complement were notbacteriocidal, the accessibility of the group B polysaccha-
ride to antibody must still be critical if complement is to be activated leading to
phagocytosis. Proving these assumptions will require additional studies exploring
the physical relationship of the group B polysaccharide with capsule polysaccharide.
The bacterial strains used in all neonatal rat protection trials were isolated from
the blood or cerebrospinal fluid of infected human neonates. Isolates ofeach capsule
type were compared for their LD5o in neonatal rats. Strains with the lowest LD5o,
generally 10-100 CFU were specifically selected for in vivo trials. In total, prophylac-
tically treated rats were challenged with two strains of each of the Ia, Ic, and III
capsule types. Several type II isolates were screened; however, none had LD5o below
our 10,000 CFU exclusion limit. Type III encapsulated strains, the most frequent
cause ofGBS meningitis in the United States, were aprimary target for therapeuticRAFF ET AL.
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trials. However, because a different serotype distribution occurs in other countries,
animal studies included a type Ia strain (25) .
The neonatal rat model was selected for in vivo studies because some aspects of
theneonatal rat'searly immunological development apparently resemble that ofhuman
neonates (26, 27). In this model, the GBS mAbs were clearly able to cross-protect
against infections caused by clinical isolates expressing different capsule types. Pro-
tection against in vivo-passed bacteria suggests the mAbs are able to reach their
target even if bacteria are grown under in vivo selective pressures. Moreover, the
mAbs were therapeutically protective when administered 4 h after infection, at a
time when GBS bacteria could be isolated from blood samples.
The antigen specificity and functional properties ofmAbs typically reflect activi-
ties present in polyclonal antisera. However, immune human sera or heterologous
antisera have not been described as possessing cross-protective activity against in-
fections caused by GBS with different capsule types. Typically, GBS antisera raised
by immunization with one serotype are protective only against infections caused
by GBS with homologous capsule types (2, 5, 10, 28). Thus it is reasonable to as-
sume that either cross-protective group B antibodies are not generated by active im-
munization, or if present, their activity is below detectable levels. In humans, be-
cause mAbs have been produced, it is more likely the relative concentration of
functional cross-protective antibody is belowthe sensitivity limits ofstandard assays.
Unfortunately, the majority ofstudiesusinghumansera possessing anti-GBS binding
activities did not specifically address the potential for protective group polysaccha-
ride antibodies (6, 29, 30). Our laboratory also has not assayed human sera for func-
tional anti-group B activity, particularly due to the difficulty preparing affinity ma-
trices that selectively remove type-specific, but not group-specific antibodies. In the
absence of studies using anti-capsule and anti-group B polysaccharide serum de-
rivedantibodies, it should notbe concludedthat sera is poorly representative ofpro-
tective group B polysaccharide antibodies. However, if sera do not generally possess
anti-group B polysaccharide protective activity, it is surprising that transformable
anti-group B polysaccharide B cells are so prevalent. These data suggest human
mAb technology may provide a means to identify nonimmunodominant epitopes
eliciting therapeutic antibodies during exposure to bacterial pathogens.
EBVcell-driven transformation ofhumanB cellswaspreviously used in ourlabo-
ratory to generate K1 capsule-specific E. coli mAbs (11). Identifying K1 mAbs was
unexpected based on the very low E. coli Kl serum antibody levels typically found
in adults (31). Theseobservations suggesthuman mAb technology has the potential
for generating mAbs with activities not apparent in sera. The GBS and E . coli Kl
(Neisseria meningitidis group B, reference 11) human mAbs provide the working basis
for a human mAb product formulation.
Summary
Group B streptococcal (GBS) infections cause significant mortality and morbidity
among infants. Passive antibody immunotherapy has been proposed as treatment
for infected infants. To this end, two human mAb-secreting cell lineswere produced
by EBV immortalization of human B cells. The mAbs were specific for the group
B polysaccharide and bound to strains ofallfive serotypes as demonstrated by ELISA91 6
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and crossed immunoelectrophoresis. The mAbs reacted and opsonized 100% (132/132)
ofthe clinical isolates tested which represented all four capsule types. Both prophylactic
and therapeutic protectionwith these mAbs were demonstrated in neonatal rats given
lethal infections of types Ia and III human clinical isolates. These data indicate that
a single human mAb directed against the group B carbohydrate can protect against
GBS infections caused by the different serotypes. This antibody may be useful in
the passive immunotherapy of infants infected with GBS.
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